The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Clinicians should identify barriers to treatment and improving clinical influenza testing, providing antiviral treatment for children with influenza-associated hospitalizations with >2 days of ...

A case of employment termination of a physician assistant (PA) who had a decade’s old contract with her employer. Was the ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

Dr. Renee Wynn is a doctorally educated, board-certified Women's Health Nurse Practitioner who focuses on perinatal and reproductive health justice. She is an Assistant Professor ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.